Is Buying Stock Like Atossa Genetics Inc. (ATOS) After Such Increase Winning Strategy?

Atossa Genetics Inc. (NASDAQ:ATOS) Logo

The stock of Atossa Genetics Inc. (NASDAQ:ATOS) is a huge mover today! The stock decreased 6.67% or $0.14 during the last trading session, reaching $1.96. About 273,216 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 3.70% since September 13, 2018 and is downtrending. It has underperformed by 3.70% the S&P500.
The move comes after 9 months positive chart setup for the $17.89 million company. It was reported on Sep, 13 by Barchart.com. We have $2.02 PT which if reached, will make NASDAQ:ATOS worth $536,820 more.

More notable recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Globenewswire.com which released: “Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient – GlobeNewswire” on March 26, 2019, also Finance.Yahoo.com with their article: “Atos and UBS Executives Join AppGuard to Support Rapid Global Expansion – Yahoo Finance” published on September 04, 2019, Globenewswire.com published: “Atos launches new unified cloud identity and access management solution for ultimate security – GlobeNewswire” on May 13, 2019. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) were released by: Seekingalpha.com and their article: “Biocept and Atossa Genetics among healthcare gainers; Quorum Health and Can-Fite BioPharma among losers – Seeking Alpha” published on March 26, 2019 as well as Seekingalpha.com‘s news article titled: “NVAX, AAOI among premarket gainers – Seeking Alpha” with publication date: June 27, 2019.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $17.89 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.